{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:28:36Z","timestamp":1757575716923,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11096-023-01693-8","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T15:04:52Z","timestamp":1707145492000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-108X","authenticated-orcid":false,"given":"Kenneth L.","family":"McCall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett J.","family":"Doughty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-445X","authenticated-orcid":false,"given":"Brian J.","family":"Piper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heeral","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seraphine","family":"Bange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily E.","family":"Leppien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12905-015-0251-9","volume":"15","author":"CM Mazure","year":"2015","unstructured":"Mazure CM, Jones DP. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research. BMC Womens Health. 2015;15:94.","journal-title":"BMC Womens Health"},{"issue":"38","key":"1693_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9380","volume":"9","author":"C Bartlett","year":"2005","unstructured":"Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9(38):1\u2013152.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1693_CR3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1089\/jwh.2017.6873","volume":"27","author":"VS Prakash","year":"2018","unstructured":"Prakash VS, Mansukhani NA, Helenowski IB, et al. Sex bias in interventional clinical trials. J Womens Health. 2018;27(11):1342\u20138.","journal-title":"J Womens Health"},{"issue":"16","key":"1693_CR4","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/cncr.28168","volume":"119","author":"K Kwiatkowski","year":"2013","unstructured":"Kwiatkowski K, Coe K, Bailar JC, et al. Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer. 2013;119(16):2956\u201363.","journal-title":"Cancer"},{"issue":"9","key":"1693_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/1747493019851292","volume":"14","author":"C Carcel","year":"2019","unstructured":"Carcel C, Woodward M, Balicki G, et al. Trends in recruitment of women and reporting of sex differences in large-scale published randomized controlled trials in stroke. Int J Stroke. 2019;14(9):931\u20138.","journal-title":"Int J Stroke"},{"issue":"7","key":"1693_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJM200008173430706","volume":"343","author":"DJ Harris","year":"2000","unstructured":"Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343(7):475\u201380.","journal-title":"N Engl J Med"},{"issue":"6","key":"1693_CR7","doi-asserted-by":"publisher","first-page":"e2113749","DOI":"10.1001\/jamanetworkopen.2021.13749","volume":"4","author":"JR Steinberg","year":"2021","unstructured":"Steinberg JR, Turner BE, Weeks BT, et al. Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020. JAMA Netw Open. 2021;4(6):e2113749.","journal-title":"JAMA Netw Open"},{"key":"1693_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106718","volume":"115","author":"AZ Sosinsky","year":"2022","unstructured":"Sosinsky AZ, Rich-Edwards JW, Wiley A, et al. Enrollment of female participants in United States drug and device phase 1\u20133 clinical trials between 2016 and 2019. Contemp Clin Trials. 2022;115:106718.","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"1693_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1089\/jwh.2009.1784","volume":"19","author":"AH Weinberger","year":"2010","unstructured":"Weinberger AH, McKee SA, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health. 2010;19(9):1727\u201332.","journal-title":"J Womens Health"},{"issue":"5","key":"1693_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/01.jcp.0000236652.78168.ee","volume":"26","author":"AC Chaves","year":"2006","unstructured":"Chaves AC, Seeman MV. Sex selection bias in schizophrenia antipsychotic trials. J Clin Psychopharmacol. 2006;26(5):489\u201394.","journal-title":"J Clin Psychopharmacol"},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/women1020009","volume":"1","author":"L Fonseca","year":"2021","unstructured":"Fonseca L, Machado V, Luersen YC, et al. Sex selection bias in schizophrenia antipsychotic trials\u2014an update systematic review. Women. 2021;1:97\u2013108.","journal-title":"Women"},{"issue":"1","key":"1693_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.18549\/PharmPract.2016.01.708","volume":"14","author":"KA Liu","year":"2016","unstructured":"Liu KA, Mager NA. Women\u2019s involvement in clinical trials: historical perspective and future implications. Pharm Pract. 2016;14(1):708.","journal-title":"Pharm Pract"},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"key":"1693_CR14","unstructured":"Guidelines for the study and evaluation of gender differences in the clinical evaluation of drugs; notice. Fed Regist. 1993;58(139):39406\u201339416."},{"key":"1693_CR15","first-page":"CD003082","volume":"11","author":"CE Adams","year":"2013","unstructured":"Adams CE, Bergman H, Irving CB, et al. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD003082.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1693_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/JCP.0000000000001041","volume":"39","author":"M Santos-Casado","year":"2019","unstructured":"Santos-Casado M, Garc\u00eda-Avello A. Systematic review of gender bias in the clinical trials of new long-acting antipsychotic drugs. J Clin Psychopharmacol. 2019;39(3):264\u201372.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1693_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","volume":"79","author":"H Taipale","year":"2022","unstructured":"Taipale H, Schneider-Thoma J, Pinz\u00f3n-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiat. 2022;79(3):210\u20138.","journal-title":"JAMA Psychiat"},{"issue":"7610","key":"1693_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/bmj.39227.616447.BE","volume":"335","author":"MM Picchioni","year":"2007","unstructured":"Picchioni MM, Murray RM. Schizophrenia. BMJ. 2007;335(7610):91\u20135.","journal-title":"BMJ"},{"issue":"5","key":"1693_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/schbul\/sbn023","volume":"35","author":"MV Seeman","year":"2009","unstructured":"Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937\u201348.","journal-title":"Schizophr Bull"},{"issue":"10","key":"1693_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","volume":"64","author":"Y Zopf","year":"2008","unstructured":"Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64(10):999\u20131004.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1693_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13293-021-00377-0","volume":"12","author":"LC Hendriksen","year":"2021","unstructured":"Hendriksen LC, van der Linden PD, Lagro-Janssen ALM, et al. Sex differences associated with adverse drug reactions resulting in hospital admissions. Biol Sex Differ. 2021;12(1):34.","journal-title":"Biol Sex Differ"},{"key":"1693_CR22","doi-asserted-by":"crossref","unstructured":"Brown E. Medical Dictionary for Regulatory Activities (MedDRA). Pharmacovigilance. John Wiley & Sons, Ltd, NJ; 2006;168\u201383","DOI":"10.1002\/9780470059210.ch13"},{"key":"1693_CR23","unstructured":"Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm. Published October 22, 2021. Accessed 10 July 2023."},{"key":"1693_CR24","unstructured":"Food and Drug Administration. National Drug Code Directory. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directory Published July 22, 2022. Accessed 10 July 2023."},{"key":"1693_CR25","unstructured":"GraphPad Prism version 9.3.0 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com. Accessed 19 July 2023."},{"key":"1693_CR26","first-page":"687","volume":"108","author":"K Wenzel-Seifert","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687\u201393.","journal-title":"Dtsch Arztebl Int"},{"key":"1693_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","volume":"24","author":"EP Harrigan","year":"2004","unstructured":"Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","volume":"34","author":"Y Ozeki","year":"2010","unstructured":"Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:401\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1693_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/jcph.257","volume":"54","author":"DA Spyker","year":"2014","unstructured":"Spyker DA, Voloshko P, Heyman ER, et al. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT\/QTc study in healthy subjects. J Clin Pharmacol. 2014;54:665\u201374.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1693_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/BF03086040","volume":"15","author":"AO Verkerk","year":"2007","unstructured":"Verkerk AO, Wilders R, Tan HL. Gender disparities in torsade de pointes ventricular tachycardia. Neth Heart J. 2007;15(12):405\u201311.","journal-title":"Neth Heart J"},{"issue":"21","key":"1693_CR31","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.270.21.2590","volume":"270","author":"RR Makkar","year":"1993","unstructured":"Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590\u20137.","journal-title":"JAMA"},{"issue":"6","key":"1693_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4088\/pcc.v05n0605","volume":"5","author":"JC Huffman","year":"2003","unstructured":"Huffman JC, Stern TA. QTc prolongation and the use of antipsychotics: a case discussion. Prim Care Companion J Clin Psychiatry. 2003;5(6):278\u201381.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"6","key":"1693_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.11909\/j.issn.1671-5411.2018.06.003","volume":"15","author":"EJ Schrijver","year":"2018","unstructured":"Schrijver EJ, Verstraaten M, van de Ven PM, et al. Low dose oral haloperidol does not prolong QTc interval in older acutely hospitalised adults: a subanalysis of a randomised double-blind placebo-controlled study. J Geriatr Cardiol. 2018;15(6):401\u20137.","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"1693_CR34","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1113\/JP270526","volume":"594","author":"DM Roden","year":"2016","unstructured":"Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016;594(9):2459\u201368.","journal-title":"J Physiol"},{"issue":"9","key":"1693_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1693_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-0447.1993.tb03326.x","volume":"87","author":"G Muscettola","year":"1993","unstructured":"Muscettola G, Pampallona S, Barbato G, et al. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993;87(1):29\u201336.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"1693_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00702-023-02589-7","volume":"130","author":"C Glocker","year":"2023","unstructured":"Glocker C, Grohmann R, Burkhardt G, et al. Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm. 2023;130(2):153\u201363.","journal-title":"J Neural Transm"},{"issue":"8","key":"1693_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archinte.165.8.869","volume":"165","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869\u201374.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1693_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ph15030298","volume":"15","author":"AC Brabete","year":"2022","unstructured":"Brabete AC, Greaves L, Maximos M, Huber E, Li A, L\u00ea ML. A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals. 2022;15(3):298.","journal-title":"Pharmaceuticals"},{"issue":"11","key":"1693_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40264-016-0455-4","volume":"39","author":"S Stergiopoulos","year":"2016","unstructured":"Stergiopoulos S, Brown CA, Felix T, et al. A survey of adverse event reporting practices among US healthcare professionals. Drug Saf. 2016;39(11):1117\u201327.","journal-title":"Drug Saf"},{"issue":"5","key":"1693_CR41","doi-asserted-by":"publisher","first-page":"e0126413","DOI":"10.1371\/journal.pone.0126413","volume":"10","author":"S Matsuda","year":"2015","unstructured":"Matsuda S, Aoki K, Kawamata T, et al. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS ONE. 2015;10(5):e0126413.","journal-title":"PLoS ONE"},{"issue":"4","key":"1693_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1693_CR43","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study. BMJ. 2022;379:e071752.","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01693-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01693-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01693-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T15:06:34Z","timestamp":1711206394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01693-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01693-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BJP was (2019\u201321) part of an osteoarthritis research team supported by Pfizer and Eli Lily. The other authors have no declarations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}